ResMed schedules October 29 results for ResMed stock
Published on 10/17/2026 at 19:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSResults date and valuation
- ResMed is scheduled to report first-quarter fiscal 2027 results on October 29, 2026.
- Fiscal 2026 revenue reached USD 5.65 billion, up 10.00 percent.
- ResMed stock was last at EUR 212.70 in Frankfurt on October 16, 2026 at 3:41 p.m. CEST, up 0.71 percent versus the Frankfurt close of October 15, 2026.
- ResMed carried a USD 33.6 billion market capitalization on October 17, 2026.
ResMed Inc. is scheduled to report its first-quarter fiscal 2027 results on October 29, 2026, according to Yahoo Finance. Fiscal 2026 revenue reached USD 5.65 billion, up 10.00 percent, while the stock was last at EUR 212.70 in Frankfurt on October 16, 2026 at 3:41 p.m. CEST, up 0.71 percent versus the Frankfurt close of October 15, 2026.
Revenue reached USD 5.65 billion
FinDog reported that ResMed's fiscal 2026 revenue rose 10.00 percent to USD 5.65 billion. Adjusted earnings per share increased 17.00 percent to USD 11.17, while fourth-quarter revenue reached USD 1.46 billion and adjusted earnings per share came to USD 2.95. The fourth quarter also included a USD 41.9 million Astral field-safety charge on the GAAP earnings line.
Stock sits 7.88 percent below its high
The Frankfurt quote stood 7.88 percent below its 52-week high of EUR 230.90 and 35.91 percent above its 52-week low of EUR 156.50 on October 16, 2026. The stock was up 1.80 percent year to date, while the reported trading volume was 2,522,452 shares against an average volume of 1,309,579 shares.
Valuation before October 29
ResMed had a USD 33.6 billion market capitalization, a P/E ratio of 22.98 and a dividend yield of 1.00 percent on October 17, 2026. MarketWatch listed 30 analyst ratings and an average target of USD 262.03 on October 16, 2026.
Comparison with peers
ResMed Inc. (NYSE, USD): minus 1.35 percent, P/E 22.98, market capitalization USD 33.6 billion.
Koninklijke Philips N.V. (NYSE, USD): plus 0.98 percent, P/E 19.97, market capitalization USD 25.2 billion.
Inspire Medical Systems, Inc. (NYSE, USD): minus 1.90 percent, P/E 14.89, market capitalization USD 2.0 billion.
What October 29 could clarify
The next report will put the USD 5.75 billion to USD 5.85 billion fiscal 2027 revenue outlook against the latest quarterly performance. The company had reported its fiscal 2026 results before the October 29 date, with the Astral charge separating GAAP and adjusted earnings growth.
Frankfurt price and coming results
ResMed stock was last at EUR 212.70 in Frankfurt on October 16, 2026 at 3:41 p.m. CEST, up 0.71 percent versus the Frankfurt close of October 15, 2026.
The further course of trading is shown by the continuously updated real-time quote of ResMed stock.
ResMed stock at a glance
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: RMD
- Primary exchange: NYSE
- Last Frankfurt price (as of October 16, 2026, 3:41 p.m. CEST): EUR 212.70
- Change versus Frankfurt close: plus 0.71 percent
- Frankfurt close (October 15, 2026): EUR 211.20
- Market capitalization: USD 33.6 billion (as of October 17, 2026)
- 52-week range: EUR 156.50-230.90 (as of October 16, 2026)
- Sector / Industry: Health care / Medical devices
- Index membership: S&P 500
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
